The Impact of COVID-19 on HTA –

Regulation bodies and HTA agencies might need to use RWE more than ever and/or re-evaluate listed technologies using the RWE to cease reimbursement of low-value health technologies due to COVID-19.

A great article about the Impact of the Pandemic on HTA by Paula K. Lorgelly and  Amanda Adler:

  • fewer resources to implement regulation and HTA
  • changing methods and priorities
  • shifting to more risk-averse approaches because of financial uncertainty

Possibility of:

  • missing more data in clinical trials
  • replacing clinical outcomes with PRO measures
  • lower thresholds
  • disconnecting between adoption decisions and budget impact
  • innovations in pricing arrangements
Share